Sign in

You're signed outSign in or to get full access.

CB

Cellectar Biosciences, Inc. (CLRB)·Q2 2025 Earnings Summary

Executive Summary

  • EPS beat: Q2 2025 diluted EPS was ($3.39) vs S&P Global consensus of ($3.70), a $0.31 beat; revenue remained $0 as expected for a pre-commercial company . Values retrieved from S&P Global.*
  • Operating discipline: Total OpEx fell 56% YoY to $6.04M on lower R&D and G&A, with net loss improving sequentially to ($5.45M) from ($6.60M) in Q1 2025 .
  • Regulatory catalysts: Management shifted to pursue an FDA NDA under the accelerated approval pathway for iopofosine I-131 in WM, contingent on sufficient funding and having the confirmatory study underway; EMA decision on potential CMA filing expected late Q3/early Q4 2025 .
  • Liquidity extended: Cash was $11.0M at 6/30/25; with July’s financing (~$5.8M net) management believes runway extends into Q2 2026, creating time to finalize partnerships to fund the WM program .

What Went Well and What Went Wrong

What Went Well

  • Breakthrough Therapy Designation (BTD) for iopofosine I-131 in WM strengthens the expedited U.S. regulatory path and supports the accelerated approval strategy .
  • Clearer regulatory plan and timing: Company now plans to file an NDA for accelerated approval, subject to funding and confirmatory study initiation; EMA advice process underway with a decision expected late Q3/early Q4 2025 .
  • Cost control and runway: OpEx decreased sharply YoY; cash plus July raise provides runway into Q2 2026, supporting ongoing regulatory engagement and pipeline steps (CLR125 Phase 1b TNBC) .

Quote

  • “We are encouraged by the recent FDA Breakthrough Therapy Designation…our regulatory strategy aligns with the FDA’s…mission to accelerate the delivery of lifesaving medicines to patients battling rare diseases, such as WM.” — CEO James Caruso .

What Went Wrong

  • Funding prerequisite remains: Management explicitly tied NDA filing and confirmatory trial start to sufficient funding or collaborations; execution risk until capital secured .
  • Non-cash warrant volatility obscures P&L: CFO flagged that warrant revaluation creates significant non-cash swings in earnings, complicating comparability and not affecting cash burn/runway .
  • Capital structure optics: Company executed a 1-for-30 reverse split in June to maintain Nasdaq compliance, a signal of valuation pressure and market access challenges .

Financial Results

Income Statement and Cash

MetricQ2 2024Q1 2025Q2 2025
Research & Development Expense ($M)$7.35 $3.43 $2.39
General & Administrative Expense ($M)$6.36 $2.97 $3.65
Total Operating Expenses ($M)$13.70 $6.40 $6.04
Net Loss ($M)$(0.92) $(6.60) $(5.45)
Diluted EPS ($)$(5.43) $(4.30) $(3.39)
Cash & Equivalents (end of period, $M)—$13.91 $11.04

Notes

  • July 2025 financing gross proceeds were ~$6.9M; PR states net proceeds of ~$5.8M; management’s runway commentary includes July funds into Q2 2026 .

Results vs Estimates (S&P Global)

MetricQ2 2025 ActualQ2 2025 ConsensusSurprise
Diluted EPS ($)(3.39)(3.70)+0.31
Revenue ($M)0.000.00In line

Values retrieved from S&P Global.*

Operating Highlights (non-GAAP adjustments context)

  • Management emphasized the non-cash nature of warrant valuation impacts in “Other income (expense),” noting these items affect EPS but not cash burn or runway .

Guidance Changes

MetricPeriodPrevious Guidance (Q1 2025)Current Guidance (Q2 2025)Change
U.S. Regulatory Path (iopofosine I-131 in WM)2025–2026Align with FDA on accelerated approval; Phase 3 RCT ~100/arm; total cost $40–45M; ~$30M to full enrollment Intend to pursue NDA for accelerated approval, subject to sufficient funding and confirmatory trial underway Updated/clarified
EMA Path (iopofosine I-131 in WM)2025Seeking conditional approval; response expected before end of Q3 2025 EMA advice ongoing; decision to submit for CMA expected late Q3 or early Q4 2025 Timeline refined
Confirmatory Study Cost/Funding2025–2026$40–45M total; ~$30M to full enrollment Reiterated total $40–45M; 25–30% of cost ($10–12M) to initiate; partnerships under active discussion Maintained with added detail
CLR125 (I-125 Auger)Late 2025/Early 2026Prepared to initiate Phase 1b/2a in TNBC (pending funding) Phase 1b dose-finding protocol submitted; targeting initiation late 2025 or early 2026 Maintained with progress
Cash Runway2025–2026Cash into Q4 2025 Cash at 6/30/25 plus July raise believed adequate into Q2 2026 Extended

Earnings Call Themes & Trends

TopicPrevious Mentions (Q4 2024 & Q1 2025)Current Period (Q2 2025)Trend
Accelerated approval for iopofosine (WM)Achieved FDA alignment; confirmatory RCT ~100/arm; 2-stage approval (MRR then PFS) Will pursue NDA under accelerated approval, subject to funding; 12-month follow-up on all patients completed; post-BTKi subset supports earlier-line confirmatory study Positive momentum, clearer path
EMA pathwaySeeking EMA conditional approval; response targeted by Q3 EMA advice ongoing; decision late Q3/early Q4 whether to submit CMA On track
Funding/partnershipsExploring strategic alternatives/licensing; preferred non-dilutive funding “Active discussions” on regional/global licensing to fund NDA and confirmatory trial Intensifying
OpEx/Cost disciplineRestructuring to reduce costs; extend runway into Q4 2025 R&D and G&A down YoY; runway into Q2 2026 including July raise Improved
Pipeline (CLR125/CLR225)IND-ready, aim to initiate Phase 1s in 2025; preclinical biodistribution/activity data CLR125 Phase 1b protocol submitted; CLR225 design described; timing late 2025/early 2026 subject to funding Advancing
Supply chainBuilding multisourcing/CDMOs Multi-isotope long-term supply agreement with Nusano (I-125 & Ac-225) De-risking supply
Capital structure/NasdaqPreparing for potential reverse split Executed 1-for-30 reverse split effective June 24, 2025 Completed action

Management Commentary

  • “We have shifted our regulatory strategy and now plan to submit a new drug application…under an accelerated approval pathway…subject to sufficient funding and having a confirmatory study underway.” — CEO James Caruso .
  • “We remain in active discussions with multiple potential partners to support the NDA filing…Such partnerships may provide non-dilutive capital that preserves stockholder value.” — CEO James Caruso .
  • “These non-cash changes [warrants] are having a significant impact on earnings, non-operating only, but do not impact cash burn or runway.” — CFO Chad Kolean .

Q&A Highlights

  • Confirmatory trial cost and initiation: Management reiterated ~$40–45M total, with ~$10–12M (25–30%) needed to initiate; NDA submission targeted after study initiation; enrollment expected to be rapid given WM community awareness and KOL support .
  • Timeline: Aim to have the confirmatory study initiated before NDA submission, with regulatory action potentially six months post-filing under expedited review timelines (BTD) .
  • Comparator arm: Investigator’s choice between rituximab monotherapy and a rituximab-based combination; historical rituximab monotherapy MRR ~22% cited as context .
  • EMA: Company anticipates EMA advice late Q3/early Q4 on whether to file for conditional marketing authorization .

Estimates Context

  • S&P Global Q2 2025 consensus EPS was ($3.70) on 3 estimates; actual diluted EPS was ($3.39), a $0.31 beat. Revenue consensus was $0.0 and matched actual $0.0. Values retrieved from S&P Global.*
  • Implications: With non-commercial status, estimate dispersion is low and concentrated on OpEx/other income; following the beat and regulatory clarity, models may shift timing assumptions for NDA and confirmatory trial spend.

Key Takeaways for Investors

  • Accelerated approval pivot is the central catalyst; funding/partnership is the gating item to NDA submission and confirmatory trial initiation .
  • Operating discipline continues; OpEx down >50% YoY and runway into Q2 2026 reduces near-term financing overhang while partnership talks proceed .
  • The EPS beat was driven amid zero revenue and ongoing R&D/G&A optimization; warrant-related non-cash items can create EPS volatility without affecting cash .
  • EMA advice outcome late Q3/early Q4 could set up a second regulatory path (EU CMA) and enhance partnering leverage .
  • Supply-chain derisked via multi-year isotope agreement (I-125, Ac-225) with Nusano, supporting both the WM program and the solid tumor pipeline .
  • Near-term pipeline milestones: CLR125 Phase 1b TNBC start targeted late 2025/early 2026 (protocol submitted); CLR225 Phase 1 design in pancreatic cancer ready, both funding-dependent .
  • Trading setup: Stock is likely to be most sensitive to (1) partnership/funding announcements enabling trial initiation/NDA filing, (2) EMA advice outcome, and (3) any additional clinical/pediatric HGG updates that reinforce the radiopharmaceutical platform .

References

  • Q2 2025 press release and financials .
  • Form 8-K and Exhibit 99.1 (Q2 2025) .
  • Earnings call transcript Q2 2025 .
  • Q1 2025 press release .
  • FY 2024/Q4 2024 press release and call .
  • Breakthrough Therapy Designation PR (June 4, 2025) .
  • Isotope supply agreement with Nusano (June 26, 2025) .
  • Reverse split PR (June 18, 2025) .

Footnote: Values retrieved from S&P Global.*